Jamaica
Tuberculosis profile
| High HIV burden |
Population  2013 2.8 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.017 (0.015–0.02) 0.62 (0.54–0.7)
Mortality (HIV+TB only) 0.014 (0.011–0.017) 0.5 (0.4–0.62)
Prevalence  (includes HIV+TB) 0.25 (0.14–0.4) 9 (4.9–14)
Incidence  (includes HIV+TB) 0.18 (0.16–0.21) 6.5 (5.9–7.4)
Incidence (HIV+TB only) 0.046 (0.035–0.053) 1.6 (1.3–1.9)
Case detection, all forms (%) 53 (47–59)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 2.4 (0.06–13) 0 (0–0)
MDR-TB cases among notified pulmonary
TB cases
2 (0–11) 0 (0–0)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 59   1
Pulmonary, clinically diagnosed 29   0
Extrapulmonary 7   0
       
Total new and relapse 96    
Previously treated, excluding relapses 0    
Total cases notified 96    
Among 96 new and relapse cases:
10 (10%) cases aged under 15 years; male:female ratio: 1.9
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 59 (100%) 0 (0%) 59
Laboratory-confirmed RR-/MDR-TB cases     1
Patients started on MDR-TB treatment     0
TB/HIV 2013 Number (%)
TB patients with known HIV status 74 (77)
HIV-positive TB patients 16 (22)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART) 14 (88)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 65
Previously treated cases, excluding relapse, registered in 2012  
HIV-positive TB cases, all types, registered in 2012 40
RR-/MDR-TB cases started on second-line treatment in 2011 100
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 0.1
Culture (per 5 million population) 0
Drug susceptibility testing (per 5 million population) 0
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) <1
% Funded domestically 100%
% Funded internationally  
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-05-28 Data: www.who.int/tb/data